Works matching DE "IPRAGLIFLOZIN"

Results: 69
    1

    Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial.

    Published in:
    Cardiovascular Diabetology, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12933-025-02745-1
    By:
    • Teragawa, Hiroki;
    • Tanaka, Atsushi;
    • Takahashi, Kanae;
    • Oshita, Chikage;
    • Uchimura, Yuko;
    • Kamei, Nozomu;
    • Hirai, Hiroyuki;
    • Shimabukuro, Michio;
    • Taguchi, Isao;
    • Okada, Yosuke;
    • Node, Koichi
    Publication type:
    Article
    2
    3
    4

    Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 4, p. 1012, doi. 10.1111/jdi.12985
    By:
    • Inoue, Hideka;
    • Morino, Katsutaro;
    • Ugi, Satoshi;
    • Tanaka‐Mizuno, Sachiko;
    • Fuse, Keiko;
    • Miyazawa, Itsuko;
    • Kondo, Keiko;
    • Sato, Daisuke;
    • Ohashi, Natsuko;
    • Ida, Shogo;
    • Sekine, Osamu;
    • Yoshimura, Masahiro;
    • Murata, Kiyoshi;
    • Miura, Katsuyuki;
    • Arima, Hisatomi;
    • Maegawa, Hiroshi
    Publication type:
    Article
    5

    Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 2, p. 429, doi. 10.1111/jdi.12913
    By:
    • Takahashi, Kiyohiko;
    • Cho, Kyu Yong;
    • Nakamura, Akinobu;
    • Miya, Aika;
    • Miyoshi, Arina;
    • Yamamoto, Chiho;
    • Nomoto, Hiroshi;
    • Niwa, Hirokatsu;
    • Takahashi, Kiyohito;
    • Manda, Naoki;
    • Kurihara, Yoshio;
    • Aoki, Shin;
    • Ito, Yoichi M;
    • Atsumi, Tatsuya;
    • Miyoshi, Hideaki
    Publication type:
    Article
    6
    7
    8
    9
    10
    11

    Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.

    Published in:
    Journal of Diabetes Investigation, 2015, v. 6, n. 6, p. 699, doi. 10.1111/jdi.12370
    By:
    • Yamada, Kentaro;
    • Nakayama, Hitomi;
    • Yoshinobu, Satoko;
    • Kawano, Seiko;
    • Tsuruta, Munehisa;
    • Nohara, Masayuki;
    • Hasuo, Rika;
    • Akasu, Shoko;
    • Tokubuchi, Ichiro;
    • Wada, Nobuhiko;
    • Hirao, Saori;
    • Iwata, Shinpei;
    • Kaku, Hiroo;
    • Tajiri, Yuji
    Publication type:
    Article
    12
    13

    Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.

    Published in:
    2017
    By:
    • Daisuke Ito;
    • Satoshi Shimizu;
    • Kazuyuki Inoue;
    • Daigo Saito;
    • Morifumi Yanagisawa;
    • Kouichi Inukai;
    • Yuji Akiyama;
    • Yoshihiro Morimoto;
    • Mitsuhiko Noda;
    • Akira Shimada;
    • Ito, Daisuke;
    • Shimizu, Satoshi;
    • Inoue, Kazuyuki;
    • Saito, Daigo;
    • Yanagisawa, Morifumi;
    • Inukai, Kouichi;
    • Akiyama, Yuji;
    • Morimoto, Yoshihiro;
    • Noda, Mitsuhiko;
    • Shimada, Akira
    Publication type:
    journal article
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.

    Published in:
    Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-05704-y
    By:
    • Okura, Tsuyoshi;
    • Fujioka, Yohei;
    • Nakamura, Risa;
    • Kitao, Sonoko;
    • Ito, Yuichi;
    • Anno, Mari;
    • Matsumoto, Kazuhisa;
    • Shoji, Kyoko;
    • Matsuzawa, Kazuhiko;
    • Izawa, Shoichiro;
    • Okura, Hiroko;
    • Ueta, Etsuko;
    • Kato, Masahiko;
    • Imamura, Takeshi;
    • Taniguchi, Shin-ichi;
    • Yamamoto, Kazuhiro
    Publication type:
    Article
    24
    25
    26

    Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.

    Published in:
    PLoS ONE, 2022, v. 17, n. 2, p. 1, doi. 10.1371/journal.pone.0261310
    By:
    • Morishita, Asahiro;
    • Tadokoro, Tomoko;
    • Fujihara, Shintaro;
    • Iwama, Hisakazu;
    • Oura, Kyoko;
    • Fujita, Koji;
    • Tani, Joji;
    • Takuma, Kei;
    • Nakahara, Mai;
    • Shi, Tingting;
    • Haba, Reiji;
    • Okano, Keiichi;
    • Nishiyama, Akira;
    • Ono, Masafumi;
    • Himoto, Takashi;
    • Masaki, Tsutomu
    Publication type:
    Article
    27
    28
    29
    30

    Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study.

    Published in:
    Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01856-x
    By:
    • Kishimoto, Shinji;
    • Higashi, Yukihito;
    • Imai, Takumi;
    • Eguchi, Kazuo;
    • Fukumoto, Kazuo;
    • Tomiyama, Hirofumi;
    • Maemura, Koji;
    • Tanaka, Atsushi;
    • Node, Koichi;
    • Murohara, Toyoaki;
    • Kitakaze, Masafumi;
    • Nishio, Yoshihiko;
    • Inoue, Teruo;
    • Ohishi, Mitsuru;
    • Kario, Kazuomi;
    • Sata, Masataka;
    • Shimabukuro, Michio;
    • Shimizu, Wataru;
    • Jinnouchi, Hideaki;
    • Taguchi, Isao
    Publication type:
    Article
    31
    32
    33

    Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.

    Published in:
    Drug Discoveries & Therapeutics, 2019, v. 13, n. 6, p. 322, doi. 10.5582/ddt.2019.01085
    By:
    • Kaoru Sugimoto;
    • Ichiro Abe;
    • Midori Minezaki;
    • Yuichi Takashi;
    • Kentaro Ochi;
    • Hideyuki Fujii;
    • Hanako Ohishi;
    • Yuka Yamao;
    • Tadachika Kudo;
    • Kenji Ohe;
    • Makiko Abe;
    • Yasushi Ohnishi;
    • Tomohiro Shinagawa;
    • Shigeaki Mukoubara;
    • Kunihisa Kobayashi
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

    Published in:
    Diabetes, Obesity & Metabolism, 2019, v. 21, n. 8, p. 1990, doi. 10.1111/dom.13750
    By:
    • Koshizaka, Masaya;
    • Ishikawa, Ko;
    • Ishibashi, Ryoichi;
    • Maezawa, Yoshiro;
    • Sakamoto, Kenichi;
    • Uchida, Daigaku;
    • Nakamura, Susumu;
    • Yamaga, Masaya;
    • Yokoh, Hidetaka;
    • Kobayashi, Akina;
    • Onishi, Shunichiro;
    • Kobayashi, Kazuki;
    • Ogino, Jun;
    • Hashimoto, Naotake;
    • Tokuyama, Hirotake;
    • Shimada, Fumio;
    • Ohara, Emi;
    • Ishikawa, Takahiro;
    • Shoji, Mayumi;
    • Ide, Shintaro
    Publication type:
    Article
    45
    46

    Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open‐label, active‐controlled study.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 11, p. 2675, doi. 10.1111/dom.13421
    By:
    • Tsurutani, Yuya;
    • Nakai, Kazuki;
    • Inoue, Kosuke;
    • Azuma, Kosuke;
    • Mukai, Sei;
    • Maruyama, Seitaro;
    • Iizuka, Takashi;
    • Matsuzawa, Yoko;
    • Saito, Jun;
    • Omura, Masao;
    • Nishikawa, Tetsuo
    Publication type:
    Article
    47

    Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2408, doi. 10.1111/dom.13394
    By:
    • Han, Kyung‐ah;
    • Chon, Suk;
    • Chung, Choon Hee;
    • Lim, Soo;
    • Lee, Kwan‐woo;
    • Baik, Seihyun;
    • Jung, Chang Hee;
    • Kim, Dong‐sun;
    • Park, Kyong Soo;
    • Yoon, Kun‐ho;
    • Lee, In‐kyu;
    • Cha, Bong‐soo;
    • Sakatani, Taishi;
    • Park, Sumi;
    • Lee, Moon‐kyu
    Publication type:
    Article
    48
    49
    50

    A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

    Published in:
    Diabetes, Obesity & Metabolism, 2015, v. 17, n. 2, p. 152, doi. 10.1111/dom.12403
    By:
    • Kashiwagi, A.;
    • Takahashi, H.;
    • Ishikawa, H.;
    • Yoshida, S.;
    • Kazuta, K.;
    • Utsuno, A.;
    • Ueyama, E.
    Publication type:
    Article